참고문헌
- Ajani JA, Moiseyenko VM, Tjulandin S, et al (2007). Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol, 25, 3205-9. https://doi.org/10.1200/JCO.2006.10.4968
- Alenzi FQ, Lotfy M, Wyse R (2010). Swords of cell death: caspase activation and regulation. Asian Pac J Cancer Prev, 11, 271-80.
- Bang YJ, Van Cutsem E, Feyereislova A, et al (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. The Lancet, 376, 687-97. https://doi.org/10.1016/S0140-6736(10)61121-X
- Barton C, Davies D, Balkwill F, et al (2005). Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin. Eur J Cancer, 41, 1474-86. https://doi.org/10.1016/j.ejca.2005.03.022
- Duman-Scheel M, Weng L, Xin S, et al (2002). Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E. Nature, 417, 299 -304. https://doi.org/10.1038/417299a
- Egloff AM, Vella LA, Finn OJ (2006). Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res, 66, 6-9. https://doi.org/10.1158/0008-5472.CAN-05-3389
- Graaf K, Hekerman P, Spelte O, et al (2004). Characterization of cyclin L2, a novel cyclin with an arginine/serine-rich domain phosphorylation by DYRK1A and colocalization with splicine factors. J Biol Chem, 279, 4612-24.
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. Ca Cancer J Clin, 6, 69-90.
- Lazzarini R, Moretti S, Orecchia S, et al (2008). Enhanced antitumor therapy by inhibion of p21waf1 in human malignant mesothelioma. Clin Cancer Res, 14, 5099-107. https://doi.org/10.1158/1078-0432.CCR-08-0255
- Li HL, Wang TS, Li XY, et al (2007). Overexpression of cyclin L2 induces apoptosis and cell-cycle arrest in human lung cancer cells. Chin Med J, 120, 905-9.
- Li S, Wang A, Jiang W, et al (2008). Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. BMC Cancer, 8, 103-11. https://doi.org/10.1186/1471-2407-8-103
- Loyer P, Trembley JH, Grenet JA, et al (2008). Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection. J Biol Chem, 283, 7721-32. https://doi.org/10.1074/jbc.M708188200
- Mori T, Anazawa Y, Matsui K, et al (2002). Cyclin K as a direct transcriptional target of the p53 tumor suppressor. Neoplasia, 4, 268 -74. https://doi.org/10.1038/sj.neo.7900235
- Ohtsu A, Shah MA, Van Cutsem E, et al (2011). Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol, 29, 3968- 76. https://doi.org/10.1200/JCO.2011.36.2236
- Redon R, Hussenet T, Bour G, et al (2002). Amplicon mapping and transcriptional analysis pinpoint cyclin L as a candidate oncogene in head and neck cancer. Cancer Res, 62, 6211-7.
- Reedijk J, Lohman PH (1985). Cisplatin: synthesis, antitumour activity and mechanism of action. Pharm Weekbl Sci, 7, 173-80. https://doi.org/10.1007/BF02307573
- Shapiro GI (2006). Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol, 24, 1770-83. https://doi.org/10.1200/JCO.2005.03.7689
- Swanton C, Marani M, Pardo O, et al (2007). Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell, 11, 498-512. https://doi.org/10.1016/j.ccr.2007.04.011
- Tabernero J, Macarulla T, Ramos FJ, et al (2005). Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol, 16, 1740-8. https://doi.org/10.1093/annonc/mdi355
- Wagner AD, Grothe W, Haerting J, et al (2006). Chemotherapy in advanced gastric cancer: A systematic review and metaanalysis based on aggregate data. J Clin Oncol, 24, 2903-9. https://doi.org/10.1200/JCO.2005.05.0245
- Yang L, Li N, Wang C, et al (2004). Cyclin L2, a novel RNA polymerase II-associated cyclin, is involved in pre-mRNA splicing and induces apoptosis of human hepatocellular carcinoma cells. J Biol Chem, 279, 11639 -48. https://doi.org/10.1074/jbc.M312895200
피인용 문헌
- Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review) vol.1, pp.6, 2013, https://doi.org/10.3892/br.2013.158
- Cross-talk between the circadian clock and the cell cycle in cancer vol.46, pp.4, 2014, https://doi.org/10.3109/07853890.2014.892296
- Knockdown of Med19 Suppresses Proliferation and Enhances Chemo-sensitivity to Cisplatin in Non-small Cell Lung Cancer Cells vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.875
- BAD, a Proapoptotic Protein, Escapes ERK/RSK Phosphorylation in Deguelin and siRNA-Treated HeLa Cells vol.11, pp.1, 2016, https://doi.org/10.1371/journal.pone.0145780
- Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas vol.143, pp.6, 2018, https://doi.org/10.1002/ijc.31418